Niven R. Narain PhD

Niven R. Narain is Co-Founder, President, & CEO of BERG. His foremost passion is to improve healthcare systems and patient care through the fusion of AI and patient biology to develop the next generation of therapeutics.

As CEO, Niven drives the vision of BERG’s translational engine from discovery to clinical development and ensures that BERG is collaborating with like-minded institutions to advance product development. He discovered Interrogative Biology®, BERG’s flagship platform that has created a robust pipeline of products in cancer, diabetes, and CNS diseases. BPM 31510 is BERG’s lead asset in solid tumors which is currently in Phase II trials. He is inventor on over 600 issued and pending patents over a diverse range of assets in drugs and diagnostics.

Niven is former Director of Cutaneous Oncology at the Miller School of Medicine where he received graduate training in cancer biology and clinical dermatology research. He is the recipient of an NIH Award of Excellence. He currently serves on the NASA Gene Lab Steering committee and oversees key DoD and academic relationships for BERG.

Niven is an industry thought leader and has spoken at events for Aspen Ideas, Wired, Economist, and Bloomberg. He was honored by the Boston Business Journal top leaders 40 under 40 (2014). He is a St. John’s University Boston Chapter alumni advisor and is an active member of the Trinity Church Boston.